177 related articles for article (PubMed ID: 37831682)
21. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD.
Boursier J; Guillaume M; Leroy V; Irlès M; Roux M; Lannes A; Foucher J; Zuberbuhler F; Delabaudière C; Barthelon J; Michalak S; Hiriart JB; Peron JM; Gerster T; Le Bail B; Riou J; Hunault G; Merrouche W; Oberti F; Pelade L; Fouchard I; Bureau C; Calès P; de Ledinghen V
J Hepatol; 2019 Aug; 71(2):389-396. PubMed ID: 31102719
[TBL] [Abstract][Full Text] [Related]
22. Defining values for controlled attenuation parameter and liver stiffness in youth without liver disease.
Ramírez-Vélez R; García-Hermoso A; Correa-Rodríguez M; Izquierdo M
Pediatr Res; 2022 Mar; 91(4):912-920. PubMed ID: 33846557
[TBL] [Abstract][Full Text] [Related]
23. Identification of patients with type 2 diabetes with non-alcoholic fatty liver disease who are at increased risk of progressing to advanced fibrosis: a cross-sectional study.
Mettananda C; Egodage T; Dantanarayana C; Fernando R; Ranaweera L; Luke N; Ranawaka C; Kottahachchi D; Pathmeswaran A; de Silva HJ; Dassanayake AS
BMJ Open; 2023 Jan; 13(1):e063959. PubMed ID: 36639212
[TBL] [Abstract][Full Text] [Related]
24. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement.
Karlas T; Petroff D; Sasso M; Fan JG; Mi YQ; de Lédinghen V; Kumar M; Lupsor-Platon M; Han KH; Cardoso AC; Ferraioli G; Chan WK; Wong VW; Myers RP; Chayama K; Friedrich-Rust M; Beaugrand M; Shen F; Hiriart JB; Sarin SK; Badea R; Lee HW; Marcellin P; Filice C; Mahadeva S; Wong GL; Crotty P; Masaki K; Bojunga J; Bedossa P; Keim V; Wiegand J
Aliment Pharmacol Ther; 2018 Apr; 47(7):989-1000. PubMed ID: 29446106
[TBL] [Abstract][Full Text] [Related]
25. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
26. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
27. [Use of a controlled attenuation parameter for the diagnosis of non-alcoholic fatty liver disease].
Goncharov AA; Sasunova AN; Pilipenko VI; Isakov VA
Ter Arkh; 2023 Oct; 95(8):641-647. PubMed ID: 38158897
[TBL] [Abstract][Full Text] [Related]
28. Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV.
Price J; Ma Y; Adimora A; Fischl M; French AL; Golub ET; Konkle-Parker D; Kuniholm MH; Ofotokun I; Plankey M; Sharma A; Tien PC
BMJ Open; 2022 Apr; 12(4):e055706. PubMed ID: 35393310
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.
Mózes FE; Lee JA; Selvaraj EA; Jayaswal ANA; Trauner M; Boursier J; Fournier C; Staufer K; Stauber RE; Bugianesi E; Younes R; Gaia S; Lupșor-Platon M; Petta S; Shima T; Okanoue T; Mahadeva S; Chan WK; Eddowes PJ; Hirschfield GM; Newsome PN; Wong VW; de Ledinghen V; Fan J; Shen F; Cobbold JF; Sumida Y; Okajima A; Schattenberg JM; Labenz C; Kim W; Lee MS; Wiegand J; Karlas T; Yılmaz Y; Aithal GP; Palaniyappan N; Cassinotto C; Aggarwal S; Garg H; Ooi GJ; Nakajima A; Yoneda M; Ziol M; Barget N; Geier A; Tuthill T; Brosnan MJ; Anstee QM; Neubauer S; Harrison SA; Bossuyt PM; Pavlides M;
Gut; 2022 May; 71(5):1006-1019. PubMed ID: 34001645
[TBL] [Abstract][Full Text] [Related]
30. The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): a tertiary referral center experience.
Fitriakusumah Y; Lesmana CRA; Bastian WP; Jasirwan COM; Hasan I; Simadibrata M; Kurniawan J; Sulaiman AS; Gani RA
BMC Gastroenterol; 2019 Mar; 19(1):43. PubMed ID: 30894137
[TBL] [Abstract][Full Text] [Related]
31. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
[TBL] [Abstract][Full Text] [Related]
32. Quantitative multiparametric magnetic resonance imaging can aid non-alcoholic steatohepatitis diagnosis in a Japanese cohort.
Imajo K; Tetlow L; Dennis A; Shumbayawonda E; Mouchti S; Kendall TJ; Fryer E; Yamanaka S; Honda Y; Kessoku T; Ogawa Y; Yoneda M; Saito S; Kelly C; Kelly MD; Banerjee R; Nakajima A
World J Gastroenterol; 2021 Feb; 27(7):609-623. PubMed ID: 33642832
[TBL] [Abstract][Full Text] [Related]
33. Point Shear Wave Elastography by ElastPQ for Fibrosis Screening in Patients with NAFLD: A Prospective, Multicenter Comparison to Vibration-Controlled Elastography.
Bauer DJ; Matic V; Mare R; Maiocchi L; Chromy D; Müllner-Bucsics T; Mandorfer M; Mustapic S; Sporea I; Ferraioli G; Grgurevic I; Reiberger T
Ultraschall Med; 2023 Apr; 44(2):169-178. PubMed ID: 35226932
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017-2018 National Health and Nutrition Examination Survey.
Ciardullo S; Monti T; Perseghin G
Clin Gastroenterol Hepatol; 2021 Feb; 19(2):384-390.e1. PubMed ID: 32623006
[TBL] [Abstract][Full Text] [Related]
35. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes.
Ciardullo S; Perseghin G
Metabolism; 2021 Aug; 121():154752. PubMed ID: 33716004
[TBL] [Abstract][Full Text] [Related]
36. NAFLD and Liver Fibrosis Are Not Associated With Reduced Femoral Bone Mineral Density in the General US Population.
Ciardullo S; Muraca E; Zerbini F; Manzoni G; Perseghin G
J Clin Endocrinol Metab; 2021 Jul; 106(8):e2856-e2865. PubMed ID: 33878156
[TBL] [Abstract][Full Text] [Related]
37. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan
Oeda S; Takahashi H; Imajo K; Seko Y; Ogawa Y; Moriguchi M; Yoneda M; Anzai K; Aishima S; Kage M; Itoh Y; Nakajima A; Eguchi Y
J Gastroenterol; 2020 Apr; 55(4):428-440. PubMed ID: 31654131
[TBL] [Abstract][Full Text] [Related]
38. Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease.
de Lédinghen V; Wong GL; Vergniol J; Chan HL; Hiriart JB; Chan AW; Chermak F; Choi PC; Foucher J; Chan CK; Merrouche W; Chim AM; Le Bail B; Wong VW
J Gastroenterol Hepatol; 2016 Apr; 31(4):848-55. PubMed ID: 26514665
[TBL] [Abstract][Full Text] [Related]
39. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
[TBL] [Abstract][Full Text] [Related]
40. High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter.
Mak LY; Chan AC; Wong TC; Dai WC; She WH; Ma KW; Sin SL; Chu KW; Seto WK; Yuen MF; Lo CM; Fung J
BMC Gastroenterol; 2023 Sep; 23(1):307. PubMed ID: 37700227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]